Cereno Scientific
7.19 SEK -2.57%3 investors are following this company
Cereno Scientific is active in biotechnology. The company specializes in drug development for common and rare cardiovascular diseases. The main drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension (PAH), as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. The head office is in Mölndal with offices also in North America.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CRNO B
Daily low / high price
6.64 / 7.5
SEK
Market cap
2.03B SEK
Turnover
32.97M SEK
Volume
4.6M
Latest videos
Financial calendar
Interim report
21.11.2024
Annual report
25.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 20.7 % | 20.2 % |
Pareto Securities AS | 5.6 % | 5.5 % |
Dory Gevryie | 1.6 % | 1.5 % |
Jan Butt | 1.4 % | 1.3 % |
Andreas Eljegard | 1.4 % | 1.3 % |
Nordnet Pensionsförsäkring AB | 1.2 % | 1.1 % |
Mårten Lundberg | 0.8 % | 0.8 % |
Niklas Borgquist | 0.7 % | 0.7 % |
Claes Sverker Jern | 0.6 % | 1.3 % |
Olof Niklas Bergh | 0.2 % | 0.9 % |
ShowingAll content types
Cereno Scientific, Webcast, 2024
Save the date for Cereno Scientific's Capital Markets Day on October 17, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools